<DOC>
	<DOCNO>NCT02885610</DOCNO>
	<brief_summary>The purpose study initially access safety effectivity RC18 combine standard treatment Placebo combine standard therapy subject Moderate severe SLE , Besides , provide dose basis follow-up clinical trial .</brief_summary>
	<brief_title>Study RC18 Administered Subcutaneously Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Active SLE disease，and least accord 4 11 item American College Rheumatology ( ACR ) criterion 1997 . Age &amp; Gender : Male female 18 65 year age inclusive，and sex ratio limit Signed inform consent form，willing able participate require study evaluation procedure . SELENASLEDAI ( Safety Estrogens Lupus Erythematosus National Assessment SLE Disease Activity Index ) score ≥ 8 screen period.and hypocomlement AntidsDNA score , SELENASLEDAI disease activity score least 6 screen . Autoantibodypositive stable SLE treatment regimen least 30 day prior Day 1 , consist follow ( alone combination ) : cortical hormone , antimalarial , nonsteroidal anti inflammatory drug ( NSAIDs ) , immunosuppressive immunomodulator therapy ( i.e. , azathioprine , mycophenolate , cyclophosphamide , methotrexate , leflunomide , Tacrolimus , ciclosporin ) . Severe lupus nephritis within two month ( design : Urine protein &gt; 6g/24h serum creatinine ( SCr） &gt; 2.5mg/dL 221umol/L ) need hemodialysis recepting high dose cortical hormone ≥14 day ( metacortandracin &gt; 100mg/d equivalent ) Central nervous system disease cause SLE non SLE within two month ( include epilepsy， mental disease，organic encephalopathy syndrome，cerebrovascular accident , encephalitis , central nervous system vasculitis） ; serious heart , liver , kidney important organ blood , endocrine system diseases medical history ; Evaluation criterion severity : 1 . Alanine aminotransferase（ALT）or aspartate aminotransferase ( AST ) ≥2 upper limit normal ( ULN ) ; 2 . Creatinine Clearance ( Ccr ) &lt; 30ml/min ; 3 . White Blood Cell Count ( WBCs ) &lt; 2.5x 10 ( 9 ) /L ; 4. hemoglobin &lt; 85g/L ; 5 . Platelets &lt; 50x 10 ( 9 ) /L . Have historically active hepatitis active hepatitis medical history , hepatitis B : Patients positive HBsAg exclude . ; Hepatitis C : Patients hepatitis C antibody positive exclude ; Immune deficiency , uncontrolled severe infection patient active recurrent peptic ulcer ; Pregnant , lactate woman men woman birth plan past 12 month ; Have history allergic reaction human biological medicine . Receipt live vaccine within 1 month ; Have participate clinical trial first 28 day initial screen 5 time halflife period study compound ( take time elderly ) . Have receive treatment B cell target therapy Rituximab Epratuzumab etc . Receipt antitumor necrosis factor、interleukin receptor antagonist； Receipt IV immunoglobulin（IVIG） , prednisone &gt; 100mg/d 14 day plasma exchange ; There active infection ( herpes zoster , human immunodeficiency virus ( HIV ) virus infection , active tuberculosis , etc . ) screen period ; Patients depression significant suicide ideation ; Investigator consider candidate appropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>